16 September 2026 editorial review · Item
T1Detect (Breakthrough T1D at-home autoantibody screening): review notes
These notes document the scope actually reviewed, including source-access limits. They are not independent clinical certification or a guarantee that every claim was verified.
Read the item evidence page →Preventing and curing evidence review — 16 September 2026
-
Disposition: corrected/updated. Current item
lastReviewed: 2026-09-16. -
Claim check: Current T1Detect ordering, price, financial assistance and shipping could not be verified from live primary ordering source. Recast old launch terms as historical, access unverified and link verified ASK alternative. Removed stale future age 1 teplizumab expansion; fixed FDA label URL. Assay validation from other DBS platforms is not proof of current kit performance.
-
Primary publication/regulatory sources checked or consulted: journal.pone.0242049; dc15-1419; jama.2013.6285; jama.2019.21565; dme.70071; dia.2023.0345; dc24-2443; tzield.pdf; 761183s013lbl.pdf.
-
Follow-up link check: former T1Detect landing page returned 404; removed it and its unverified current-panel attribution. The December 2020 launch announcement remains indexed historical evidence, explicitly not a current offer. Consolidated teplizumab labeling to correctly titled June 2026 prescribing information.